Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in the chronic obstructive pulmonary disease (COPD) market, threatening the position of LAMA, LAMA/LABA, and LABA/ICS FDCs. The market entry of the inhaled phosphodiesterase (PDE)-3 / PDE-4 inhibitor Ohtuvayre and the approval of the interleukin (IL)-4 / IL-13 inhibitor Dupixent for COPD provide added treatment options for patients with moderate to severe disease. The launch and uptake of generic versions of blockbuster inhaled drugs (e.g., salmeterol / fluticasone, formoterol / budesonide, albuterol sulfate) increases the affordability of treatment, further changing prescribing patterns.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed COPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed COPD patients?
- How have Trelegy, Breztri, Ohtuvayre, and Dupixent been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of COPD patients receive drug therapy within one year of diagnosis, and how quickly?
- What percentage of patients progress to later lines of therapy within one year of diagnosis? What percentage of COPD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Allegra, Zyrtec, Xolair, Benadryl, montelukast, Vistaril, Silenor, Humira, Dupixent
Key analyses: Brand / therapy usage across longitudinal patient sample; Newly diagnosed patient analysis; Treatment initiation and progression; Line of therapy analysis; Combination therapy analysis; Source of business for recently treated patients; Persistency and compliance analysis; Product-level patient flow charts
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
